Nader Dbouk1, Miguel R Arguedas, Aasim Sheikh. 1. Department of Internal Medicine, The University of Alabama at Birmingham, 1530 3rd Avenue South BDB 327, Birmingham, AL 35294, USA. ndbouk@gmail.com
Abstract
BACKGROUND AND OBJECTIVES: We examined the test characteristics of the PHQ-9, a new screening tool that has been validated in the general population but not amongst patients with hepatitis C virus (HCV). METHODS: The PHQ-9, CES-D and BDI-II questionnaires were administered to 129 consecutive patients with chronic HCV attending a specialty clinic between August 2005 and April 2006. RESULTS: Approximately 52% of participants reported symptoms suggesting depression. Prevalence of depression was 62% using the BDI-II, 75% per the PHQ-9 and 72% per the CES-D. We observed a strong correlation between the BDI-II, CES-D and PHQ-9 in patients on and off interferon. Scores on the three questionnaires were only moderately associated with symptoms reported by the patients. There was moderate agreement between the CES-D and BDI-II and slight agreement between both these questionnaires and the PHQ-9. Scores on the PHQ-9 correlated strongly with scores on the CES-D and BDI-II and moderately with patients' symptoms.
BACKGROUND AND OBJECTIVES: We examined the test characteristics of the PHQ-9, a new screening tool that has been validated in the general population but not amongst patients with hepatitis C virus (HCV). METHODS: The PHQ-9, CES-D and BDI-II questionnaires were administered to 129 consecutive patients with chronic HCV attending a specialty clinic between August 2005 and April 2006. RESULTS: Approximately 52% of participants reported symptoms suggesting depression. Prevalence of depression was 62% using the BDI-II, 75% per the PHQ-9 and 72% per the CES-D. We observed a strong correlation between the BDI-II, CES-D and PHQ-9 in patients on and off interferon. Scores on the three questionnaires were only moderately associated with symptoms reported by the patients. There was moderate agreement between the CES-D and BDI-II and slight agreement between both these questionnaires and the PHQ-9. Scores on the PHQ-9 correlated strongly with scores on the CES-D and BDI-II and moderately with patients' symptoms.
Authors: Brennan M R Spiegel; Zobair M Younossi; Ron D Hays; Dennis Revicki; Sean Robbins; Fasiha Kanwal Journal: Hepatology Date: 2005-04 Impact factor: 17.425
Authors: Juan Fernando Gallegos-Orozco; Ana Paula Fuentes; Juan Gerardo Argueta; Christian Pérez-Pruna; Carlos Hinojosa-Becerril; Ma Sara Sixtos-Alonso; Socorro Cruz-Castellanos; Gabriela Gutiérrez-Reyes; Marco Antonio Olivera-Martínez; Ma Concepción Gutiérrez-Ruiz; David Kershenobich Journal: Arch Med Res Date: 2003 Mar-Apr Impact factor: 2.235
Authors: P Hauser; J Khosla; H Aurora; J Laurin; M A Kling; J Hill; M Gulati; A J Thornton; R L Schultz; A D Valentine; C A Meyers; C D Howell Journal: Mol Psychiatry Date: 2002 Impact factor: 15.992
Authors: Shawn M Kneipp; John A Kairalla; Jeanne Marie R Stacciarini; Deidre Pereira; M David Miller Journal: Nurs Res Date: 2010 Nov-Dec Impact factor: 2.381
Authors: James R Rodrigue; William Balistreri; Barbara Haber; Maureen M Jonas; Parvathi Mohan; Jean P Molleston; Karen F Murray; Michael R Narkewicz; Philip Rosenthal; Lesley J Smith; Kathleen B Schwarz; Patricia Robuck; Bruce Barton; Regino P González-Peralta Journal: J Pediatr Gastroenterol Nutr Date: 2009-03 Impact factor: 2.839